These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6523017)

  • 1. [Myelomatous bone. Histomorphometric study and therapeutic effects].
    Charhon SA; Valentin-Opran A; Edouard C; Delmas PD; Meunier PJ
    Rev Rhum Mal Osteoartic; 1984 Dec; 51(11):657-62. PubMed ID: 6523017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative histology of myeloma-induced bone changes.
    Valentin-Opran A; Charhon SA; Meunier PJ; Edouard CM; Arlot ME
    Br J Haematol; 1982 Dec; 52(4):601-10. PubMed ID: 7138789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Bone histology in postmenopausal osteoporosis--variations in cellular activity].
    Lozo P; Krpan D; Krvavica A; Vukelić Baturić T; Fistonić I; Kusec V
    Acta Med Croatica; 2004; 58(1):5-11. PubMed ID: 15125387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of tiludronate on bone loss in paraplegic patients.
    Chappard D; Minaire P; Privat C; Berard E; Mendoza-Sarmiento J; Tournebise H; Basle MF; Audran M; Rebel A; Picot C
    J Bone Miner Res; 1995 Jan; 10(1):112-8. PubMed ID: 7747617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Histomorphometric and biological data on osteoporosis due to immobilization].
    Minaire P; Meunier P; Edouard C; Bernard J; Courpron P
    Rev Rhum Mal Osteoartic; 1975; 42(7-9):479-88. PubMed ID: 1179130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
    Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone response to invading tumors with spindle cell components: a report of findings in two patients.
    Gruber HE; Schwinn CP; Kirchen ME; Moore TM; Marshall GJ
    J Lab Clin Med; 1992 Oct; 120(4):639-44. PubMed ID: 1402340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bone histomorphometry in monoclonal dysglobinemia. Diagnostic and prognostic value].
    Grauer JL; Blanc D; Zagala A; Sotto JJ; Duplan B; Drevet JG; Phelip X
    Rev Rhum Mal Osteoartic; 1986 Oct; 53(10):517-23. PubMed ID: 3797975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
    Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
    Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy.
    Favia G; Pilolli GP; Maiorano E
    Bone; 2009 Sep; 45(3):406-13. PubMed ID: 19450715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Histomorphometric study of nonpagetic bone in Paget patients. Results before and after diphosphonates].
    Coindre JM; Edouard CM; Arlot ME; Meunier PJ
    Rev Rhum Mal Osteoartic; 1982 Feb; 49(2):103-9. PubMed ID: 7063793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Bisphosphonates in the treatment and prevention of bone metastases].
    Hoekman K; van Holten-Verzantvoort AT; Pinedo HM
    Ned Tijdschr Geneeskd; 1997 Nov; 141(46):2217-22. PubMed ID: 9550782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aredia: the once-monthly infusion for the treatment of bone metastases.
    Lipton A
    Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S1-5. PubMed ID: 9801852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bisphosphonates in the treatment of multiple myeloma].
    Stajszczyk M
    Przegl Lek; 2002; 59(1):37-42. PubMed ID: 12108045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates in multiple myeloma.
    Apperley JF; Croucher PI
    Pathol Biol (Paris); 1999 Feb; 47(2):178-81. PubMed ID: 10192885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The skeleton in primary hyperparathyroidism: a review focusing on bone remodeling, structure, mass, and fracture.
    Christiansen P
    APMIS Suppl; 2001; (102):1-52. PubMed ID: 11419022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
    Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
    Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic application of sequential bone marrow biopsy in myeloma: analysis of 13 medullary biopsies].
    Paule B; Médicis P; Clerc D; Bennet P; Bisson M; Massias P
    Biomed Pharmacother; 1986; 40(7):261-4. PubMed ID: 3814757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.